Project Grant R41AR074345

Award Date 9/20/18
Completion Date 8/31/20
Dollars Obligated $0
Federal Grant Program
93.846
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94107, USA
Similar Awards
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) supports the development of an ultrasound-coupled electrical impedance tomography (US-EIT) device for assessing sarcopenia, a condition involving loss of skeletal muscle mass and function. The $275,762 award to Rytek Medical Inc. will be used to design a sonolucent electrode array and housing that integrates with a standard ultrasound probe, enabling quantitative evaluation of muscle health through...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Phase I Small Business Innovation Research (SBIR) project aims to develop a novel implantable system that leverages distraction osteogenesis as a treatment for diabetic foot ulcers (DFUs). The $295,000 award, effective from December 15, 2024 to August 31, 2025, supports the design and development of a low-profile implantable transverse tibial transport device. This device integrates an active mechanical...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS), under the Biomedical Research and Research Training program (CFDA 93.859), provides $699,738 to Sagespectra Inc. to develop and validate a wireless patch for post-surgical monitoring and electrotherapy of surgical flaps. The key products to be delivered include: A prototype wireless patch that can remotely monitor surgical flap health by measuring tissue oxygenation (StO2), relative temperature, and...
This $100,000 National Science Foundation project grant supports the development of a novel multi-wavelength spectroscopy technique and portable analyzer to assess tissue health at Texas A&M Engineering Experiment Station in College Station, Texas. The goal is to prevent pressure injuries through early detection by evaluating tissue oxygenation and blood perfusion beneath the skin's surface, which could help hospitals decrease injury rates and costs. The proposed technology may identify...
RCE Technologies, Inc. was awarded a $255,892 Small Business Innovation Research Phase I Project Grant from the National Science Foundation's Technology, Innovation, and Partnerships program to develop a proof-of-concept machine learning-based diagnostic system for detecting myocardial infarction and ischemia in real-time. The system aims to provide point-of-care clinical classification for heart attack cases using a novel, portable device integrating the awardee's proprietary external...
This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $303,000 to Saint Louis University to develop a small animal tensiometer for noninvasively measuring in vivo muscle forces and to evaluate the effectiveness of electrically stimulated eccentric contraction (ESEC) training on improving muscle function following volumetric muscle loss (VML) injury in a rodent model. The...
This National Science Foundation (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) Project Grant award of $274,976 to Ecate LLC aims to develop a novel intraspinal stimulator system to restore sensation and volitional motor control in spinal cord injury patients. The project will fabricate nanopatterned stimulating electrodes coupled with custom CMOS chips to deliver spatially selective electrical stimulation to the spinal cord. This closed-loop neural interface system is intended...
The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded a $295,481 Project Grant under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to Inprint Bio LLC, a for-profit limited liability company located in Farmington, CT. The goal of this project is to develop and evaluate "MUSCLEINK", a multifunctional colloidal scaffold for the treatment of volumetric muscle loss (VML). VML is a condition that results in substantial...
This Project Grant award from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), under the Discovery and Applied Research for Technological Innovations to Improve Human Health program (CFDA 93.286), aims to develop a wireless, battery-free bioelectronic implant for closed-loop neuromodulation to manage detrusor sphincter dyssynergia (DSD) in spinal cord injury (SCI) patients. The $206,132 award to the University of Houston System will fund the fabrication and validation...
This Project Grant award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846), is developing the X-Visual, a sensor to track fracture healing in cannulated screws used for hip fracture fixation. The $299,999 award to Aravis Biotech LLC will cover the design, computational modeling, and initial testing of this innovative device that can non-invasively measure screw bending...

TECHNOLOGY FOR THE NON-INVASIVE SURVEILANCE OF POST-TRAUMATIC COMPARTMENT SYNDROME - PROJECT SUMMARY ACUTE COMPARTMENT SYNDROME (ACS) REMAINS ONE OF THE MOST DEVASTATING AND OFTEN OVERLOOKED TRAUMATIC MUSCULOSKELETAL DISORDERS IN CLINICAL PRACTICE. IN THIS CONDITION, PRESSURE INCREASES IN ONE OF THE BODY'S SPACE- LIMITED COMPARTMENTS, DUE MOST COMMONLY TO DIRECT TRAUMA OR BONE FRACTURE, RESULTING ULTIMATELY IN AN ISCHEMIC INJURY TO ALL OF THE COMPARTMENT'S CONTENTS, INCLUDING MUSCLE AND NERVE. ONCE A FULL-BLOWN COMPARTMENT SYNDROME DEVELOPS, THE CONSEQUENCES ARE UNIFORMLY CATASTROPHIC, WITH PERMANENT MUSCLE AND NERVE LOSS, SOMETIMES NECESSITATING AMPUTATION OF THE ENTIRELY NON-FUNCTIONAL LIMB. IF CAUGHT BEFORE IRREVOCABLE DAMAGE IS DONE, AGGRESSIVE SURGICAL DECOMPRESSION, VIA FASCIOTOMY, CAN BE PERFORMED TO RELIEVE THE PRESSURE IN THE COMPARTMENT AND ALLOWING THE MUSCLES AND NERVES TO RECOVER. HOWEVER, CURRENT APPROACHES FOR ASSESSING THE DEVELOPMENT OF ACS, OUTSIDE OF THE PHYSICAL EXAMINATION, ARE LIMITED. THE STANDARD METHOD INVOLVES THE INSERTION OF A PRESSURE MONITOR. THERE ARE NO EFFECTIVE APPROACHES FOR THE CONTINUOUS SURVEILLANCE FOR THE DEVELOPMENT OF ACS AFTER AN INJURY. ONE TECHNOLOGY THAT MAY BE ESPECIALLY SENSITIVE TO THE DEVELOPMENT OF ACS IS THAT OF ELECTRICAL IMPEDANCE MYOGRAPHY (EIM). IN EIM, A WEAK, HIGH-FREQUENCY ELECTRICAL CURRENT IS PASSED BETWEEN A NUMBER OF ELECTRODES OVERLYING A MUSCLE OR MUSCLE GROUP OF INTEREST AND THE RESULTING SURFACE VOLTAGES MEASURED BY A SECOND SET OF ELECTRODES. THE HEALTH STATUS OF THE UNDERLYING MUSCLE IMPACTS THE MEASURED VOLTAGES IN CONSISTENT AND PREDICTABLE FASHION. FOR INSTANCE, INCREASING MYOFIBER EDEMA AND INJURY WOULD BE EXPECTED TO LEAD TO REDUCTIONS IN THE IMPEDANCE RESISTANCE MEASURE. THE DEVELOPMENT OF EIM FOR MEDICAL AND BROADER HEALTH USE IS THE UNDERLYING FOCUS OF MYOLEX, INC, A SMALL BUSINESS CONCERN BASED IN SAN FRANCISCO AND BOSTON. TO DATE, THE TECHNOLOGY HAS BEEN SHOWN TO BE EFFECTIVE IN A WIDE VARIETY OF DISORDERS THAT IMPACT THE MUSCLE EITHER DIRECTLY OR INDIRECTLY, INCLUDING MUSCULAR DYSTROPHY, AMYOTROPHIC LATERAL SCLEROSIS, AND SARCOPENIA (MUSCLE WASTING IN THE ELDERLY). ADDITIONAL WORK HAS ALSO SUGGESTED THAT EIM IS SENSITIVE TO PRIMARY MUSCLE INJURY. IN THIS STUDY WE PROPOSE TO EXTEND THIS WORK, SEEKING TO DEVELOP EIM AS A NON-INVASIVE, CONVENIENT MONITORING TOOL TO ASSESS THE DEVELOPMENT OF ACS. THIS WILL ALLOW HEALTH CARE PROFESSIONALS TO MONITOR COMPARTMENTS FOR ACS AFTER PREDISPOSING INJURY INTERVENE AND TO INTERVENE AT A SUFFICIENTLY EARLY POINT, SO AS TO AVOID PERMANENT INJURY. IN OUR FIRST SPECIFIC AIM, WE WILL USE A RAT ACS MODEL TO ASSESS CHANGES IN EIM VALUES AND THE CORRESPONDING ALTERATIONS IN PATHOLOGY AT SEVERAL SEVERITIES OF INJURY TO ESTABLISH A TIME COURSE OF CHANGE AND THE RELATIONSHIP TO IMPEDANCE VALUES. IN SPECIFIC AIM 2, USING TISSUE DATA OBTAINED IN AIM 1 AND ANATOMIC MODELS, WE WILL DESIGN ELECTRODE ARRAYS THAT WILL BE MOST EFFECTIVE AT DETECTING THE DEVELOPMENT OF ACS IN A PORCINE MODEL AND IN HUMAN SUBJECTS FOR USE IN OUR PLANNED PHASE 2 STUDIES.

Posted 2/4/21, 12:00 AM